Clinical trials: AMD
Retinal Degeneration, Retinitis Pigmentosa
Stem Cells Therapy in Degenerative Diseases of the Retina
The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Age Related Macular Degeneration, Stargardt Disease 1
- Trial name
- NCT03772938
- Testing
- Stem/progenitor cells transplantation
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Pomeranian Medical University Szczecin
Macular Edema, Branch Retinal Vein Occlusion
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results.
- Trial name
- Revolution (NCT01247220)
- Testing
- Ranibizumab, Peripheral Laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Retina Associates of Florida, P.A.
Ophthalmopathy, Wet Macular Degeneration
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
AMD (age-related macular degeneration), is the leading cause of blindness in individuals over the age of 55. There is no cure for wet-AMD but anti-VEGF treatments significantly minimize the vision loss over time.
- Trial name
- PAMER (NCT04982484)
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Age-related Macular Degeneration
Efficacy of Laser Acupuncture on Zanzhu (BL02) for Dry Age-related Macular Degeneration
This study is to see if laser acupuncture is a better way to treat dry-AMD (Age-related Macular Degeneration) compared to sham laser acupuncture, in the aspect of visual acuity.
- Trial name
- NCT06264947
- Testing
- laser acupuncture
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Age-Related Macular Degeneration
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is the main reason older people lose their vision. It affects the macula, the center of the retina needed for sharp, clear vision.
- Trial name
- NCT02564978
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Eye Institute (NEI)
Glycogen Storage Disease Type II, Pompe Disease
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II
GSD-II (also known as Pompe disease) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
- Conditions
- Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2
- Trial name
- NCT00051935
- Testing
- Alglucosidase alfa
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Genzyme, a Sanofi Company
Age Related Macular Degeneration
Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing
The current norm in clinical practice for the treatment of choroidal neovascular membranes (CNVM) secondary to Age-related Macular Degeneration(AMD) involves monthly injections of Ranibizumab until the disease is stabilized.
- Trial name
- NCT01453920
- Testing
- Ranibizumab
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University Health Network, Toronto
Age-Related Macular Degeneration
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of…
- Trial name
- NCT05803785
- Testing
- BBC1501
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Benobio Co., Ltd.
Macular Degeneration, Choroidal Neovascularization
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with…
- Trial name
- NCT00433017
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 255 people
- Sponsor
- Novartis
Pompe Disease
Pregnancy and Birth Outcome in Women With Pompe Disease
This study explores the outcome and effect of pregnancy on Pompe Disease. The results are expected to guide clinicians in counseling and care of women with Pompe disease, who are planning to become pregnant, and during the…
- Trial name
- NCT01556516
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- O & O Alpan LLC
Pompe Disease
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
Pompe disease is an inherited condition of acid alpha-glucosidase (GAA) deficiency resulting in lysosomal accumulation of glycogen in all tissues. Glycogen accumulation leads to muscle dysfunction and profound muscle weakness.
- Trial name
- NCT00976352
- Testing
- rAAV1-CMV-GAA (study agent) Administration, RMST
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Florida
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Exudative Macular Degeneration
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and…
- Trial name
- NCT05093374
- Testing
- anti-VEGF agent
- Where
- Austria
- Volunteers
- 290 people
- Sponsor
- Medical University of Vienna
Stargardt Disease 1, STGD1
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following…
- Conditions
- Stargardt Disease 1, STGD1, Healthy Volunteers
- Trial name
- NCT07836452
- Testing
- CITY-RBP4
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- City Therapeutics
Choroidal Neovascularization, Macular Degeneration
Fluocinolone Implant to Treat Macular Degeneration
This study will test the safety and effectiveness of a fluocinolone implant to treat age-related macular degeneration. This eye disease can severely impair central vision, affecting a person's ability to read, drive, and carry…
- Trial name
- NCT00008515
- Testing
- Fluocinolone
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema…
- Trial name
- Tejas (NCT05387837)
- Testing
- D-4517.2
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Macular Degeneration
Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)
Optical Coherence Tomography (OCT) is an established non-invasive medical imaging technique ophthalmologists use to diagnose and monitor retinal diseases such as age-related macular degeneration (AMD).
- Trial name
- NCT02555995
- Testing
- OCT scan (as yet unnamed)
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Bern
Macular Degeneration
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
The purpose of this study is to determine the association of bevacizumab and PDT is safety and effective in the treatment of exudative AMD
- Trial name
- NCT00684853
- Testing
- bevacizumab, vetaporfin
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Wet Macular Degeneration
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01249937)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Macular Edema, Epiretinal Membrane
Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane
This study seeks to evaluate the effect of the intravitreal 0.7mg dexamethasone implant on central macular thickness and visual acuity in those patients with persistent macular edema after pars plana vitrectomy for epiretinal…
- Conditions
- Macular Edema, Epiretinal Membrane, Vitrectomy
- Trial name
- DEMO (NCT02995746)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Wills Eye
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.